79 research outputs found

    L’esthesioneuroblastome olfactif : a propos de 7

    Get PDF
    Introduction : L’esthésioneuroblastome est une tumeur maligne rare développée aux dépens du neuro-épithélium olfactif. C’est l’une des plus rares tumeurs des fosses nasales. L’objectif de ce travail est d’étudier à travers une revue de la littérature, les caractéristiques histocliniques, les modalités thérapeutiques et les facteurs pronostiques de cette tumeur.Matériel et méthodes : Etude rétrospective à propos de sept cas d’esthésioneuroblastome olfactif traités dans le service d’ORL et de CCF de l’hôpital Farhat Hached de Sousse sur une période de 26 ans.Résultats : L’âge moyen de nos patients était de 36 ans avec une prédominance féminine. La symptomatologie clinique était dominée par l’obstruction nasale et l’épistaxis. Cinq patients étaient classés stade B de Kadish, et 2 stade C. Six patients ont eu un traitement chirurgical dont cinq ont eu une radiothérapie post opératoire. Une patiente avait une importante extension locorégionale et était au dessus de tout traitement à visée curative. Trois malades sont en rémission complète avec un recul moyen de 6 ans. Trois malades ont présenté une récidive tumorale.Conclusion : L’esthésioneuroblastome olfactif est une tumeur naso-sinusienne maligne rare, caractérisée par son polymorphisme clinique et son agressivité locale. Malgré la chirurgie et la radiothérapie, le pronostic reste réservé à long terme.Mots clés : Esthésioneuroblastome olfactif - Imagerie- Immunohistochimie- Chirurgie -RadiothérapieIntroduction: Introduction: Esthesioneuroblastoma is a rare malignant tumor, which develops from olfactory neuroepithelium and is one of the rarest tumors of the nasal cavity. The aim of this study is to specify through a review of the literature, histoclinic characteristics, therapeutic terms and prognostic factors of this tumor.Material and methods: a retrospective study concerning seven cases of olfactory neuroblastoma treated in the department of otolaryngology- Head and Neck surgery at Farhat Hached Hospital Sousse over a period of 26 years.Results: The mean age of our patients was 36 years. A female predominance was noted. Clinical symptomatology was dominated by nasal obstruction and epistaxis. Five patients were classified as Kadish B and 2 patients as Kadish C. Six patients underwent surgicaltreatment, five of them had postoperative radiotherapy. One patient was above all therapeutic resources. 3 patients are in complete remission with a mean follow-up of 6 years. Recurrence was observed for the remaining patients.Conclusion: olfactory esthesioneuroblastoma is a rare sinonasal malignant tumor, characterised by clinical polymorphism and local agressivity. In spite of the surgery and the radiotherapy, the forecast remains reserved in the long term.Key words: Olfactory neuroblastoma – Imagery – Immunohistochemestry – Surgery - Radiotherap

    Production, bleaching and characterization of pulp from Stipa tenacissima

    Get PDF
    Alfa grass pulping was successfully performed in hydro-organic acid medium under mild conditions (107°C, atmospheric pressure, cooking time: 3 h). Use of an acetic acid/formic acid/water mixture as pulping liquor was perfectly suitable for selective isolation of pulp, lignin, and hemicelluloses. The unbleached pulp obtained in good yield was first delignified by peroxyacids in organic acid medium and then bleached with hydrogen peroxide in a basic medium to give pulp offering good physico-chemical and mechanical characteristics

    Inhibitors of retrograde trafficking active against ricin and Shiga toxins also protect cells from several viruses, Chlamydiales and Leishmania

    Get PDF
    Medical countermeasures to treat biothreat agent infections require broad-spectrum therapeutics that do not induce agent resistance. A cell-based high-throughput screen (HTS) against ricin toxin combined with hit optimization allowed selection of a family of compounds that meet these requirements. The hit compound Retro-2 and its derivatives have been demonstrated to be safe in vivo in mice even at high doses. Moreover, Retro-2 is an inhibitor of retrograde transport that affects syntaxin-5- dependent toxins and pathogens. As a consequence, it has a broad-spectrum activity that has been demonstrated both in vitro and in vivo against ricin, Shiga toxin-producing O104:H4 enterohemorrhagic E. coli and Leishmania sp. and in vitro against Ebola, Marburg and poxviruses and Chlamydiales. An effect is anticipated on other toxins or pathogens that use retrograde trafficking and syntaxin-5. Since Retro-2 targets cell components of the host and not directly the pathogen, no selection of resistant pathogens is expected. These lead compounds need now to be developed as drugs for human use

    Aryl transition metal chemical warheads for protein bioconjugation

    No full text
    The past seven years have witnessed the burgeoning of protein bioconjugation reactions highlighting aryl transition metal reagents as coupling partners. This new bioorthogonal organometallic chemistry, which sets the scene for stoichiometric processes in place of the catalytic procedures that developed in parallel, already enabled the forging of C-S and C-C bonds onto protein substrates, respectively in their native state or equipped with pre-installed non-natural terminal alkene or alkyne appendages. Although not yet applied to proteins, related transformations pointing to the creation of C-N bonds have, in addition, just been disclosed by targeting peptide lysine residues. Central to this research was the selection of ligands attached to the transition metal, in order to confer to metal complexes, not only their stability in aqueous medium, but also the desired chemoselectivity. We summarize here this body of work, which has already put in the limelight elaborated palladium and gold complexes equipped with biologically relevant appendages, such as fluorescent and affinity tags, as well as drug molecules. This research holds much promise, not only for the study of proteins themselves, but also for the design of new protein-based biotherapeutics, such as protein-drug conjugates or constrained analogs resulting from macrocyclisation reactions

    Production and structure prediction of amylases from Chlorella vulgaris

    No full text
    International audienc
    • …
    corecore